BioLineRx (NASDAQ:BLRX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX opened at $0.10 on Friday. BioLineRx has a 1 year low of $0.08 and a 1 year high of $1.44. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The stock’s fifty day moving average price is $0.26 and its two-hundred day moving average price is $0.49. The firm has a market cap of $8.11 million, a PE ratio of -0.46 and a beta of 1.46.

BioLineRx’s stock is going to reverse split on the morning of Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 29th.

Institutional Investors Weigh In On BioLineRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Atria Investments Inc grew its position in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares in the last quarter. PVG Asset Management Corp purchased a new stake in BioLineRx during the 2nd quarter worth about $70,000. Finally, CVI Holdings LLC bought a new position in BioLineRx in the 2nd quarter worth about $462,000. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.